Buy, Hold, or Sell: Lam Research Rocketed 21% Off Its June Lows as a New Fed Begins. Is LRCX Worthwhile at $366?

Lam Research reported Q3 FY26 revenue of $5.84 billion, up 23.76% year over year, and non-GAAP EPS of $1.47 versus $1.3633 consensus, while June-quarter guidance calls for $6.60 billion in revenue and $1.65 EPS. The stock has surged 20.95% in the past week to $366.81, but that leaves it above the $323.38 analyst consensus target and near valuation-heavy levels around 47x forward earnings. Bulls cite AI-driven wafer-fab equipment demand and a $140 billion WFE outlook, while bears point to China exposure at 34% of revenue, insider selling, and softer free cash flow.

Analysis

The market is starting to re-rate Lam as an AI infrastructure beneficiary, but the cleaner read is that this is a high-beta multiple expansion trade masquerading as a fundamentals story. In semicap, the first move is usually driven by order visibility and guidance inflection; the second move depends on whether customers translate AI enthusiasm into sustained tool spending, especially at the memory and packaging layers. That means the next leg is less about one quarter of upside and more about whether hyperscaler-related capex remains broad enough to support multi-quarter WFE resilience.

The key second-order effect is that Lam’s mix exposes it to the most capital-intensive parts of the stack, which makes it a leverage play on both demand and export-policy stability. Any tightening in China controls would hit not just revenue but also booking confidence, because fabs tend to defer tool decisions when policy risk rises. Conversely, if memory makers and advanced packaging customers keep spending through the next two quarters, the group should see a positive read-through to other process-tool names with similar etch/deposition exposure and to select materials vendors that benefit from higher chamber utilization.

The contrarian point is that the stock’s reaction has likely front-loaded a lot of the good news, while free cash flow softness suggests the quality of earnings is not yet fully confirming the price action. A premium multiple can be justified if growth persists, but not if the market is merely discounting a cyclical peak in AI spend. The likely path is not a clean melt-up; it is a consolidation or air-pocket if the next catalyst fails to exceed already-elevated expectations.

Risk is two-fold: over days to weeks, the chart can mean-revert as fast-money longs monetize the recent squeeze; over months, the real threat is a deceleration in hyperscaler capex commentary or a China policy headline that compresses visibility. The setup improves materially only if the next guidance step-up is accompanied by broader order momentum, not just one segment carrying the quarter.

Key Decisions for Investors

• Avoid chasing LRCX here; wait for a pullback/retest toward the low-$330s before initiating longs, where the forward multiple should compress enough to re-establish a better risk/reward over a 4-8 week horizon.
• For tactical exposure to AI capex, prefer a pair trade: long LRCX / short a weaker semicap peer with less pricing power or higher China sensitivity, sized for a 1-3 month catalyst window and capped if LRCX holds above $375.
• Use call spreads rather than outright stock for upside participation: buy 3-6 month LRCX call spreads with strikes roughly 5-10% above spot to reduce premium bleed if the stock consolidates after the recent squeeze.
• Hedge China/export-control risk by pairing any LRCX long with a small short in a China-exposed semiconductor index basket; this protects the thesis if policy headlines hit the group over the next 1-2 quarters.
• If hyperscaler capex commentary weakens into the next earnings cycle, de-risk semicap longs broadly; that would be the first sign that the AI spend trade is transitioning from multi-quarter growth to a shorter cyclical burst.